September 19, 2023
The Japanese health ministry on September 15 granted orphan drug designation to four APIs including Novartis Pharma’s BRAF inhibitor Tafinlar (dabrafenib) and MEK inhibitor Mekinist (trametinib). Tafinlar and Mekinist were designated for the treatment of BRAF V600 -mutated relapsed or...read more